14 Recruiting Squamous Cell Carcinoma of the Head and Neck Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceTop Recruiting Squamous Cell Carcinoma of the Head and Neck Studies
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic
Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck
📍 UCSD Moores Cancer Center — La Jolla, California
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
📍 Emory University Hospital Midtown — Atlanta, Georgia
View Study & Checklist ➔ 🟡 Not Yet Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
Safety and Efficacy Trial of TV5M01 for Radiation-Induced Mucositis in Head and Neck Cancer Patients.
📍 Fundación Valle del Lili — Cali, Valle del Cauca Department
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
📍 Research Site — Tucson, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
Ipilimumab for Head and Neck Cancer Patients
📍 Portland Providence Medical Center — Portland, Oregon
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic
Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔